CoChat

ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.

Abstract

Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is typically initiated by inactivation of the von Hippel Lindau ( VHL) gene, which results in the constitutive activation of the hypoxia inducible factors, HIF-1α and HIF-2α. Using a high throughput screen, we identify novel compounds that decrease HIF-1/2α levels and induce ferroptosis by targeting Iron Sulfur Cluster Assembly 2 (ISCA2), a component of the late mitochondrial Iron Sulfur Cluster (L-ISC) assembly complex. ISCA2 inhibition either pharmacologically or using siRNA decreases HIF-2α protein levels by blocking iron-responsive element (IRE)-dependent translation, and at higher concentrations, also decreases HIF-1α translation through unknown mechanisms. Additionally, ISCA2 inhibition triggers the iron starvation response, resulting in iron/metals overload and death via ferroptosis. ISCA2 levels are decreased in ccRCC compared to normal kidney, and decreased ISCA2 levels are associated with pVHL loss and with sensitivity to ferroptosis induced by ISCA2 inhibition. Strikingly, pharmacological inhibition of ISCA2 using an orally available ISCA2 inhibitor significantly reduced ccRCC xenograft growth in vivo, decreased HIF-α levels and increased lipid peroxidation, suggesting increased ferroptosis in vivo. Thus, the targeting of ISCA2 may be a promising therapeutic strategy to inhibit HIF-1/2α and to induce ferroptosis in pVHL deficient cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-022-02460-1

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification and characterization of novel HIF-2α selective inhibitors. A Screening flow-chart for the identification of selective small molecule inhibitors of HIF-2α. B, C Validation of HIF-1α or HIF-2α dependency of a Hypoxia Responsive Element (HRE)-driven luciferase reporter construct stably expressed in (B) 786-0 or (C) MIAPaCa-2 cells. D (i) 786-0 HRE-Luciferase dose-response assays of indicated compounds (24-hour treatment) with IC50 values (μM) indicated in brackets; (ii) Chemical structures of compounds used in the study. E Western blots showing effects of treatment with #1 or #25 on levels of HIF-2α and other proteins in 786-0 cells in normoxia (20% O2). F Effects of 24- or 72-hours’ treatment with #1 in ACHN cells (exposed to hypoxia or 1% O2 for the final 24 h). G Effects of treatment of, (i) RCC10 cells with #25 ± proteasomal inhibitor, MG132 (5 μM 24 h, 20% O2), or of (ii) hypoxic ACHN cells with #1 ± MG132 (24 h, 1% O2) on HIF-1α and HIF-2α. H Quantitative RT-PCR showing effects of #25 on the transcription of HIF2A (EPAS1) and HIF-2 target genes VEGFA and OCT-3/4 (POU5F1). I Effect of #25 treatment on luciferase activity driven by a HIF-2α Iron-Responsive Element (IRE)-luciferase reporter construct stably expressed in 786-0 cells. The iron chelator, deferoxamine (DFO; 50 μM), and iron donor, ferric acetylcysteine (FAC; 25 µM) were used to confirm responsiveness of the reporter to iron perturbation. All data shown are representative of at least 2 independent experiments and show the mean ± SEM. *p < 0.05; **p < 0.01.
Fig. 1 Identification and characterization of novel HIF-2α selective inhibitors. A Screening flow-chart for the identification of selective small molecule inhibitors of HIF-2α. B, C Validation of HIF-1α or HIF-2α dependency of a Hypoxia Responsive Element (HRE)-driven luciferase reporter construct stably expressed in (B) 786-0 or (C) MIAPaCa-2 cells. D (i) 786-0 HRE-Luciferase dose-response assays of indicated compounds (24-hour treatment) with IC50 values (μM) indicated in brackets; (ii) Chemical structures of compounds used in the study. E Western blots showing effects of treatment with #1 or #25 on levels of HIF-2α and other proteins in 786-0 cells in normoxia (20% O2). F Effects of 24- or 72-hours’ treatment with #1 in ACHN cells (exposed to hypoxia or 1% O2 for the final 24 h). G Effects of treatment of, (i) RCC10 cells with #25 ± proteasomal inhibitor, MG132 (5 μM 24 h, 20% O2), or of (ii) hypoxic ACHN cells with #1 ± MG132 (24 h, 1% O2) on HIF-1α and HIF-2α. H Quantitative RT-PCR showing effects of #25 on the transcription of HIF2A (EPAS1) and HIF-2 target genes VEGFA and OCT-3/4 (POU5F1). I Effect of #25 treatment on luciferase activity driven by a HIF-2α Iron-Responsive Element (IRE)-luciferase reporter construct stably expressed in 786-0 cells. The iron chelator, deferoxamine (DFO; 50 μM), and iron donor, ferric acetylcysteine (FAC; 25 µM) were used to confirm responsiveness of the reporter to iron perturbation. All data shown are representative of at least 2 independent experiments and show the mean ± SEM. *p < 0.05; **p < 0.01.CC BY · PubMed Central
Fig. 2 ISCA2 is the molecular target of HIF-α inhibitors. A Schematic showing sample preparation workflow for DARTS assay. Lysates from ACHN cells that were exposed to 1% O2 for 16 h were divided into 4 equal samples and subjected to indicated treatments. B (i) Mass spectrometry data from DARTS assay indicating intensity of ISCA2 fragments in cell lysates treated with Pronase together with #1 or DMSO (Con); (ii) Western blot showing effects of control or Pronase treatment in ACHN cell lysates treated with indicated concentrations of #1. Densitometric analysis of ISCA2 band intensities normalized to actin is shown above blots. B, C Thermal shift assays showing effects of incubation of recombinant ISCA2 (4 μg) with (B) DMSO (green) or 200 μM #1 (magenta), or (C) DMSO (green) or 100 µM #25 (red). Quantitation of ISCA2 melting temperatures are shown inset (mean ± SEM). D Effects of transfections with non-targeting (Con) or ISCA2 (A2) siRNA on indicated proteins in hypoxic ACHN cells. Knockdown was performed using two consecutive siRNA transfections over 72 h each. E–G Iron content of 786-0 cells treated with (E) #1, (F) #25, for 24 h; or (G) transfected with siCon or siISCA2 (6 days) as determined using ICP-MS.
Fig. 2 ISCA2 is the molecular target of HIF-α inhibitors. A Schematic showing sample preparation workflow for DARTS assay. Lysates from ACHN cells that were exposed to 1% O2 for 16 h were divided into 4 equal samples and subjected to indicated treatments. B (i) Mass spectrometry data from DARTS assay indicating intensity of ISCA2 fragments in cell lysates treated with Pronase together with #1 or DMSO (Con); (ii) Western blot showing effects of control or Pronase treatment in ACHN cell lysates treated with indicated concentrations of #1. Densitometric analysis of ISCA2 band intensities normalized to actin is shown above blots. B, C Thermal shift assays showing effects of incubation of recombinant ISCA2 (4 μg) with (B) DMSO (green) or 200 μM #1 (magenta), or (C) DMSO (green) or 100 µM #25 (red). Quantitation of ISCA2 melting temperatures are shown inset (mean ± SEM). D Effects of transfections with non-targeting (Con) or ISCA2 (A2) siRNA on indicated proteins in hypoxic ACHN cells. Knockdown was performed using two consecutive siRNA transfections over 72 h each. E–G Iron content of 786-0 cells treated with (E) #1, (F) #25, for 24 h; or (G) transfected with siCon or siISCA2 (6 days) as determined using ICP-MS.CC BY · PubMed Central
Fig. 3 ISCA2 depletion decreases HIF-1/2α levels and promotes iron and metals accumulation. A Western blots showing effect of 6-day siRNA knockdown of ISCA1 (A1), ISCA2 (A2), IBA57 (A57) or non-targeting siRNA (Con) in ACHN cells in 20% O2 or after 6 h at 1% O2 ± the proteasome inhibitor MG132 (5 μM and 1 μM for 6 h in 20% and 1% O2 respectively). Densitometric analysis of ISCA2 band intensities normalized to GAPDH is shown in S3A. B Effect of 2- and 4-day knockdown of ISCA2 using a second ISCA2 siRNA construct (A#2) in ACHN cells in 1% O2. Densitometric analysis of ISCA2 band intensities normalized to actin is shown above blots. C Effect of 6-day knockdown with indicated siRNAs in RCC4 cells. D Effect of transfection of indicated siRNAs on the transcription of HIF1A and EPAS1 normalized to B2M in ACHN cells. E Effect of ISCA2 siRNA on HIF-1/2α translation in RCC4 cells. Cells were transfected with ISCA2 siRNA for 3 days, then labelled with puromycin. Puromycin incorporation was determined by immunoprecipitation of HIF-1/2α followed by western blot using an antibody against puromycin. F Effect of 5-day siRNA knockdowns on metals accumulation in ACHN cells detected using ICP-MS. Approximately equal cell numbers were submitted for analysis. All data are representative or averages of at least two independent experiments shown as mean ± SEM.
Fig. 3 ISCA2 depletion decreases HIF-1/2α levels and promotes iron and metals accumulation. A Western blots showing effect of 6-day siRNA knockdown of ISCA1 (A1), ISCA2 (A2), IBA57 (A57) or non-targeting siRNA (Con) in ACHN cells in 20% O2 or after 6 h at 1% O2 ± the proteasome inhibitor MG132 (5 μM and 1 μM for 6 h in 20% and 1% O2 respectively). Densitometric analysis of ISCA2 band intensities normalized to GAPDH is shown in S3A. B Effect of 2- and 4-day knockdown of ISCA2 using a second ISCA2 siRNA construct (A#2) in ACHN cells in 1% O2. Densitometric analysis of ISCA2 band intensities normalized to actin is shown above blots. C Effect of 6-day knockdown with indicated siRNAs in RCC4 cells. D Effect of transfection of indicated siRNAs on the transcription of HIF1A and EPAS1 normalized to B2M in ACHN cells. E Effect of ISCA2 siRNA on HIF-1/2α translation in RCC4 cells. Cells were transfected with ISCA2 siRNA for 3 days, then labelled with puromycin. Puromycin incorporation was determined by immunoprecipitation of HIF-1/2α followed by western blot using an antibody against puromycin. F Effect of 5-day siRNA knockdowns on metals accumulation in ACHN cells detected using ICP-MS. Approximately equal cell numbers were submitted for analysis. All data are representative or averages of at least two independent experiments shown as mean ± SEM.CC BY · PubMed Central
Fig. 4 SiRNA knockdown or pharmacological inhibition of ISCA2 induces cell death. A (i–iii) Effect of indicated siRNAs on total protein content in indicated cell lines (6 days post-transfection). B Media appearance of ACHN cells transfected with indicated siRNAs for 5 days. C Viable cell number determined by trypan blue exclusion in ACHN cells 5 days after transfection with indicated siRNAs. D Cell viability assay of 786-0 cells transfected with indicated siRNAs. Cells were seeded into 96-well plates 6 days after siRNA transfection, and cell viability was measured using resazurin daily for 6 days. E Effect of indicated siRNA on PS exposure in 786-0 cells 28 h after transfection. TRAIL (400 ng/ml, 4 h) is a positive control. F Effect of siRNA transfection in causing loss of membrane permeability in 786-0 cells 72 h after transfection using TRAIL (400 ng/ml, 72 h) as a positive control. Data shown are the mean ± SEM.
Fig. 4 SiRNA knockdown or pharmacological inhibition of ISCA2 induces cell death. A (i–iii) Effect of indicated siRNAs on total protein content in indicated cell lines (6 days post-transfection). B Media appearance of ACHN cells transfected with indicated siRNAs for 5 days. C Viable cell number determined by trypan blue exclusion in ACHN cells 5 days after transfection with indicated siRNAs. D Cell viability assay of 786-0 cells transfected with indicated siRNAs. Cells were seeded into 96-well plates 6 days after siRNA transfection, and cell viability was measured using resazurin daily for 6 days. E Effect of indicated siRNA on PS exposure in 786-0 cells 28 h after transfection. TRAIL (400 ng/ml, 4 h) is a positive control. F Effect of siRNA transfection in causing loss of membrane permeability in 786-0 cells 72 h after transfection using TRAIL (400 ng/ml, 72 h) as a positive control. Data shown are the mean ± SEM.CC BY · PubMed Central
Fig. 5 ISCA2 inhibition induces ferroptosis. A Effect of co-treatment of ISCA2 siRNA and DMSO or liproxstatin (2.5 μM) on cell viability determined using resazurin in ACHN cells. siRNA transfection was performed for a total of 5 days with liproxstatin (or DMSO) added for the last 24 h. B, C Cell viability assays (resazurin) of 786-0 cells treated with (B) #1 or (C) #25, ± DFO (100 μM), liproxstatin (1 μM) or ZVAD-FMK (20 μM); or (H) #25 ± DFO (100 μM), NAC (1 mM), liproxstatin (1 μM) or ZVAD-FMK (20 μM). Treatments were performed for 24 h. Average IC50 values (µM) are shown in brackets. D Impact of #25 treatment (48 h) on BODIPY 581/591 fluorescence detected by flow cytometry in 786-0 cells. E Impact of 48 hours’ treatment with #25, PT2385 (PT) or 6 hours’ treatment with RSL3 on malondialdehyde (MDA), an indicator of lipid peroxidation in RCC10 cells. F Transmission electron microscopy of RCC10 cells treated with DMSO or #25 for 24 h (2 representative micrographs of each condition). DMSO-treated cells show normal mitochondria whereas #25-treated cells show damaged mitochondria including lost or irregular cristae (white arrows) and irregular matrix with voids (yellow arrows).
Fig. 5 ISCA2 inhibition induces ferroptosis. A Effect of co-treatment of ISCA2 siRNA and DMSO or liproxstatin (2.5 μM) on cell viability determined using resazurin in ACHN cells. siRNA transfection was performed for a total of 5 days with liproxstatin (or DMSO) added for the last 24 h. B, C Cell viability assays (resazurin) of 786-0 cells treated with (B) #1 or (C) #25, ± DFO (100 μM), liproxstatin (1 μM) or ZVAD-FMK (20 μM); or (H) #25 ± DFO (100 μM), NAC (1 mM), liproxstatin (1 μM) or ZVAD-FMK (20 μM). Treatments were performed for 24 h. Average IC50 values (µM) are shown in brackets. D Impact of #25 treatment (48 h) on BODIPY 581/591 fluorescence detected by flow cytometry in 786-0 cells. E Impact of 48 hours’ treatment with #25, PT2385 (PT) or 6 hours’ treatment with RSL3 on malondialdehyde (MDA), an indicator of lipid peroxidation in RCC10 cells. F Transmission electron microscopy of RCC10 cells treated with DMSO or #25 for 24 h (2 representative micrographs of each condition). DMSO-treated cells show normal mitochondria whereas #25-treated cells show damaged mitochondria including lost or irregular cristae (white arrows) and irregular matrix with voids (yellow arrows).CC BY · PubMed Central
Fig. 6 VHL loss promotes sensitivity to ISCA2 inhibition. A ISCA2 levels in pVHL mutant ccRCC cells ± stable pVHL reconstitution. B Resazurin cell viability assay of 786-0 parental or 786-0 cells with pVHL reconstitution transfected with indicated siRNAs (24 h post-transfection). C, D Representative plot showing viability (resazurin) of RCC4 and RCC4 + VHL cells (C), and 786-0 and 786-0 +VHL cells (D), after treatment with #25 for 24 h. IC50 values (μM) are shown in brackets. E Western blots showing levels of endogenous (Endo) and overexpressed FLAG-ISCA2 in stable clones expressing empty vector (Vec) or ISCA2 from 786-0 and RCC10 cells (2 ISCA2 clones each). F, G Representative plots showing viability of RCC10 (F), or 786-0 (G) cells stably expressing empty vector (Vec) or ISCA2 treated with #25 for 24 h. IC50 values (μM) are shown in brackets. H Representative plots showing viability of RCC10 cells stably expressing empty vector (Vec) or ISCA2 treated with Erastin for 24 h. IC50 values (μM) are shown in brackets.
Fig. 6 VHL loss promotes sensitivity to ISCA2 inhibition. A ISCA2 levels in pVHL mutant ccRCC cells ± stable pVHL reconstitution. B Resazurin cell viability assay of 786-0 parental or 786-0 cells with pVHL reconstitution transfected with indicated siRNAs (24 h post-transfection). C, D Representative plot showing viability (resazurin) of RCC4 and RCC4 + VHL cells (C), and 786-0 and 786-0 +VHL cells (D), after treatment with #25 for 24 h. IC50 values (μM) are shown in brackets. E Western blots showing levels of endogenous (Endo) and overexpressed FLAG-ISCA2 in stable clones expressing empty vector (Vec) or ISCA2 from 786-0 and RCC10 cells (2 ISCA2 clones each). F, G Representative plots showing viability of RCC10 (F), or 786-0 (G) cells stably expressing empty vector (Vec) or ISCA2 treated with #25 for 24 h. IC50 values (μM) are shown in brackets. H Representative plots showing viability of RCC10 cells stably expressing empty vector (Vec) or ISCA2 treated with Erastin for 24 h. IC50 values (μM) are shown in brackets.CC BY · PubMed Central
Fig. 7 ISCA2 is decreased in ccRCC and low ISCA2 is associated with poor patient prognosis. A Immunohistochemistry showing representative expression of ISCA2 in normal kidney (top) and in ccRCC (bottom). B Quantitation of ISCA2 H-Score in paired uninvolved and ccRCC cores from 19 patients. ****p < 0.0001 determined via Mann Whitney test. C, D Kaplan–Meier curves showing associations of (C) ISCA2 protein, or (D) ISCA2 transcript levels above (high) or below (low) the median with overall survival using a tumor microarray (TMA; 94 cases) or data from TCGA-KIRC (522 cases) respectively.
Fig. 7 ISCA2 is decreased in ccRCC and low ISCA2 is associated with poor patient prognosis. A Immunohistochemistry showing representative expression of ISCA2 in normal kidney (top) and in ccRCC (bottom). B Quantitation of ISCA2 H-Score in paired uninvolved and ccRCC cores from 19 patients. ****p < 0.0001 determined via Mann Whitney test. C, D Kaplan–Meier curves showing associations of (C) ISCA2 protein, or (D) ISCA2 transcript levels above (high) or below (low) the median with overall survival using a tumor microarray (TMA; 94 cases) or data from TCGA-KIRC (522 cases) respectively.CC BY · PubMed Central
Fig. 8 ISCA2 inhibition inhibits xenograft growth in vivo. A, B Effect of treatment of 786-0 subcutaneous xenografts with vehicle or indicated doses of compound #25 (8 mice/group) administered orally once daily, on tumor volume (A), or mouse body weights (B). **p < 0.01; ***p < 0.001; ****p < 0.0001 from Students’ T-tests of vehicle versus 60 mg/kg treated group. p was not significant (NS) for 30 mg/kg treated group versus vehicle. C Effect of treatment of RENCA subcutaneous xenografts in syngeneic Balb/c mice with vehicle or 60 mg/kg #25 (8 mice/group) once daily. D Western blots showing HIF-1α and GAPDH with densitometric values normalized to GAPDH below. E MDA content of RENCA tumors from mice treated with vehicle or 60 mg/kg #25. F Proposed model for effects of ISCA2 blockade. Inhibition of ISCA2 using either small molecules or siRNA results in perceived iron deprivation, which induces upregulation of IRP2, TFRC and downregulation of FTH1, that together promote iron/metals accumulation that triggers cell death via ferroptosis, and also drives the later downregulation of IRP1, IRP2 and TFRC. This perceived iron deprivation also drives a shift to the IRE-binding form of IRP1 which inhibits HIF-2α translation. ISCA2 inhibition may also cause other mitochondrial/extramitochondrial defects dependent or independent of perceived iron deprivation that inhibits the translation of HIF-1α through unknown mechanisms. Thus, ISCA2 inhibition depletes both HIF-1α and HIF-2α and promotes cell death via ferroptosis.
Fig. 8 ISCA2 inhibition inhibits xenograft growth in vivo. A, B Effect of treatment of 786-0 subcutaneous xenografts with vehicle or indicated doses of compound #25 (8 mice/group) administered orally once daily, on tumor volume (A), or mouse body weights (B). **p < 0.01; ***p < 0.001; ****p < 0.0001 from Students’ T-tests of vehicle versus 60 mg/kg treated group. p was not significant (NS) for 30 mg/kg treated group versus vehicle. C Effect of treatment of RENCA subcutaneous xenografts in syngeneic Balb/c mice with vehicle or 60 mg/kg #25 (8 mice/group) once daily. D Western blots showing HIF-1α and GAPDH with densitometric values normalized to GAPDH below. E MDA content of RENCA tumors from mice treated with vehicle or 60 mg/kg #25. F Proposed model for effects of ISCA2 blockade. Inhibition of ISCA2 using either small molecules or siRNA results in perceived iron deprivation, which induces upregulation of IRP2, TFRC and downregulation of FTH1, that together promote iron/metals accumulation that triggers cell death via ferroptosis, and also drives the later downregulation of IRP1, IRP2 and TFRC. This perceived iron deprivation also drives a shift to the IRE-binding form of IRP1 which inhibits HIF-2α translation. ISCA2 inhibition may also cause other mitochondrial/extramitochondrial defects dependent or independent of perceived iron deprivation that inhibits the translation of HIF-1α through unknown mechanisms. Thus, ISCA2 inhibition depletes both HIF-1α and HIF-2α and promotes cell death via ferroptosis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 74

Metadata

Authors
Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., Sirohi, D., Agarwal, N., Liu, X., & Koh, M. Y.
Affiliations
  • University of Utah (US)
  • Sanford Burnham Prebys Medical Discovery Institute (US)
  • ARUP Institute for Clinical and Experimental Pathology (US)
Corresponding author
Koh, Mei Yee
Venue
Oncogene
Published
2022-09-12
Volume
41
Issue
42
Pages
4709-4723
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W4295292877
Cited by
69
References
81
Citations by year
2026: 18 · 2025: 13 · 2024: 21 · 2023: 17
FWCI
8.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217905, R43 CA217385-A1)
  • U.S. Department of Defense (PKG00251547)
  • U.S. Department of Health & Human Services | National Institutes of Health (R43 CA217385-A1, T32DK007115)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
iron-sulfur cluster assembly, ferroptosis, clear cell renal cell carcinoma, HIF-1α, HIF-2α, VHL, iron-responsive element, iron starvation response, lipid peroxidation, iron overload, anticancer drug screening, xenograft tumor growth inhibition
MeSH terms
Ferroptosis, Endothelial PAS Domain-Containing Protein 1, Carcinoma, Renal Cell, Humans, Iron-Sulfur Proteins, Kidney Neoplasms, Gene Expression Regulation, Neoplastic, RNA, Small Interfering, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. https://app.cochat.ai/papers/10.1038/s41388-022-02460-1
The paper
Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., Sirohi, D., Agarwal, N., Liu, X., & Koh, M. Y. (2022). ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene. https://doi.org/10.1038/s41388-022-02460-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.